Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Equillium Inc (NQ: EQ )

1.150 +0.060 (+5.52%)
Streaming Delayed Price Updated: 3:36 PM EDT, Aug 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Equillium Inc

< Previous 1 2 3 4 5 Next >
Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates
From Equillium, Inc.
Via Business Wire
Equillium to Present at Two Upcoming Investor Conferences
From Equillium, Inc.
Via Business Wire
Equillium Presents Clinical Data from EQUALISE Phase 1b Study in Lupus Patients at the American Society of Nephrology Annual Meeting
From Equillium, Inc.
Via Business Wire
Equillium Presents Interim Safety Data from First Cohort of Asthma Patients in Phase 1b EQUIP Study at the American College of Allergy, Asthma & Immunology Meeting
From Equillium, Inc.
Via Business Wire
Equillium Announces Two Abstracts Accepted for Presentation at the 63rd ASH Annual Meeting and Exposition
From Equillium, Inc.
Via Business Wire
Equillium Reveals Early Safety Data For Itolizumab In Lupus Patients
Equillium Inc (NASDAQ: EQ) announced interim data from the Type A portion of the Phase 1b EQUALISE study in systemic lupus erythematosus (SLE) patients. Data were... 
Via Benzinga
Equillium Announces Interim Safety Data and Reduction in Proteinuria for Lupus Patients Treated with Itolizumab in the EQUALISE Study Presented at the ACR Annual Meeting
From Equillium, Inc.
Via Business Wire
Equillium Announces Two Abstracts Accepted for Presentation at the Upcoming Virtual 2021 American Society of Nephrology Annual Meeting
From Equillium, Inc.
Via Business Wire
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Equillium Announces Multiple Abstracts Accepted for Presentation at ACR Convergence 2021
From Equillium, Inc.
Via Business Wire
Equillium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
From Equillium, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2021
Upgrades For Alcoa Corp (NYSE: 
Via Benzinga
Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From Equillium, Inc.
Via Business Wire
60 Biggest Movers From Yesterday
Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pfizer for $18.50 per share,... 
Via Benzinga
Equillium's Itolizumab Reduces Urine Protein In Lupus Patients
Equillium Inc (NASDAQ: EQ) announced additional data from the Type A portion of the EQUALISE Phase 1b study of itolizumab in systemic lupus erythematosus (SLE) and... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Hims & Hers Health (NYSE:HIMS)... 
Via Benzinga
Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis
From Equillium, Inc.
Via Business Wire
Equillium Reports Second Quarter 2021 Financial Results and Provides Clinical Development Update
From Equillium, Inc.
Via Business Wire
Equillium to Present at the BTIG Virtual Biotechnology Conference
From Equillium, Inc.
Via Business Wire
Equillium's Single Phase 3 Study In aGVHD To Support US Filing Of Itolizumab
Equillium Inc (NASDAQ: EQ) completed an End-of-Phase 1 meeting with the FDA, confirming to advance itolizumab into a single Phase 3 pivotal study in first-line... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 12) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers SCWorx (NASDAQ:WORX) shares rose... 
Via Benzinga
64 Biggest Movers From Friday
Gainers Kanzhun Limited (NASDAQ: BZ) shares climbed 95.8% to close at $37.20 on Friday after the company priced its IPO at $19 per share. Novan, Inc. (NASDAQ: NOVN) shares gained... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Novan (NASDAQ:NOVN) stock rose 71.04% to $15.46 during Friday's regular session. As of 12:30 EST, Novan's stock is trading at a volume of 109.3 million,... 
Via Benzinga
Equillium's Itolizumab Shows Rapid, Durable Responses In Graft-Versus-Host-Disease Patients
Equillium Inc (NASDAQ: EQ) has announced positive topline data from the Phase 1b EQUATE study evaluating itolizumab in first-line acute graft-versus-host-disease (... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Aethlon Medical (NASDAQ:AEMD) stock rose 248.41% to $7.7 during Wednesday's pre-market session. The market value of their outstanding shares is at $93.4... 
Via Benzinga
46 Biggest Movers From Yesterday
Gainers Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) shares jumped 27.3% to close at $9.79 on Tuesday after the company reported inducement grants. The company recently said it... 
Via Benzinga
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.